The case for adjuvant chemotherapy in pancreatic cancer.

  title={The case for adjuvant chemotherapy in pancreatic cancer.},
  author={Paula Ghaneh and Asma Sultana and Susannah Shore and Deborah D. Stocken and John P Neoptolemos},
  journal={Best practice & research. Clinical gastroenterology},
  volume={20 2},
Pancreatic cancer is a difficult cancer to treat effectively. Only a small proportion of patients are suitable for resection. The long-term survival following resection alone is between 10 and 18%. Adjuvant therapy aims to improve this outcome. There have been five fully reported adjuvant trials in pancreatic cancer. The largest study is the ESPAC-1 trial which demonstrated a significant survival benefit for 5-fluorouracil chemotherapy and no survival benefit for adjuvant chemoradiotherapy. A… CONTINUE READING